Increased Set1 binding at the promoter induces aberrant epigenetic alterations and up-regulates cyclic adenosine 5'-monophosphate response element modulator alpha in systemic lupus erythematosus

Abstract

BackgroundUp-regulated cyclic adenosine 5'-monophosphate response element modulator α (CREMα) which can inhibit IL-2 and induce IL-17A in T cells plays a critical role in the pathogenesis of systemic lupus erythematosus (SLE). This research aimed to investigate the mechanisms regulating CREMα expression in SLE.ResultsFrom the chromatin immunoprecipitation (ChIP) microarray data, we found a sharply increased H3 lysine 4 trimethylation (H3K4me3) amount at the CREMα promoter in SLE CD4+ T cells compared to controls. Then, by ChIP and real-time PCR, we confirmed this result. Moreover, H3K4me3 amount at the promoter was positively correlated with CREMα mRNA level in SLE CD4+ T cells. In addition, a striking increase was observed in SET domain containing 1 (Set1) enrichment, but no marked change in mixed-lineage leukemia 1 (MLL1) enrichment at the CREMα promoter in SLE CD4+ T cells. We also proved Set1 enrichment was positively correlated with both H3K4me3 amount at the CREMα promoter and CREMα mRNA level in SLE CD4+ T cells. Knocking down Set1 with siRNA in SLE CD4+ T cells decreased Set1 and H3K4me3 enrichments, and elevated the levels of DNMT3a and DNA methylation, while the amounts of H3 acetylation (H3ac) and H4 acetylation (H4ac) didn’t alter greatly at the CREMα promoter. All these changes inhibited the expression of CREMα, then augmented IL-2 and down-modulated IL-17A productions. Subsequently, we observed that DNA methyltransferase (DNMT) 3a enrichment at the CREMα promoter was down-regulated significantly in SLE CD4+ T cells, and H3K4me3 amount was negatively correlated with both DNA methylation level and DNMT3a enrichment at the CREMα promoter in SLE CD4+ T cells.ConclusionsIn SLE CD4+ T cells, increased Set1 enrichment up-regulates H3K4me3 amount at the CREMα promoter, which antagonizes DNMT3a and suppresses DNA methylation within this region. All these factors induce CREMα overexpression, consequently result in IL-2 under-expression and IL-17A overproduction, and contribute to SLE at last. Our findings provide a novel approach in SLE treatment.Electronic supplementary materialThe online version of this article (doi:10.1186/s13148-016-0294-2) contains supplementary material, which is available to authorized users.

Reduced expression of hematopoietic progenitor kinase 1 in T follicular helper cells causes autoimmunity of systemic lupus erythematosus

“…4,5 The Tfh cells have been proved to play an important role in the pathogenesis of SLE, with a significantly increased proportion in the peripheral blood circulation of patients with SLE. The expressions of IL-21 6 , BAFF, 7 IFNγ, 8 and IL-17A 9 are significantly higher in SLE patients than that in normal controls. IL-21 is the main cytokine for Tfh cells to execute effector functions and promote the differentiation and maturation of B cells, generation of plasma cells, production and class conversion of immunoglobulin.…”

Comparative Analysis on Abnormal Methylome of Differentially Expressed Genes and Disease Pathways in the Immune Cells of RA and SLE

“…CD4 + T cells from SLE patients have hypomethylation in the promoter and enhancer regions of ITGAL and TNFSF7 (80,81). Similarly, the changes in the methylation status of CD40L, FOXP3, RFX1, and CREM led to changes in the expression of downstream signals affecting disease progression in SLE (82)(83)(84)(85). Interestingly, many changes in methylation profiles of B cells observed in RA and SLE were also closely related to disease manifestations (86).…”

Aberrant RNA Splicing Events Driven by Mutations of RNA-Binding Proteins as Indicators for Skin Cutaneous Melanoma Prognosis

“…Both genetic and epigenetic alterations that interfere with normal cell physiological function are the fundamental reason of tumorigenesis (3)(4)(5)(6)(7). Alterations in transcriptome provide one of the biggest possibilities of proteome and molecular diversity of human cells.…”